Drug intelligence / Profile preview

Alaska

Development stage: Preclinical
Lead developer: Tikun Olam
Modality: Small Molecules
Administration: Inhalation, Oral, Sublingual

Overview

Alaska is a high-THC, Sativa-dominant botanical cannabis strain developed by Tikun Olam. It primarily acts as an agonist at the Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2) within the endocannabinoid system. The strain is designed to address symptoms associated with cancer (such as nausea and loss of appetite), PTSD, chronic pain, and multiple sclerosis. It is characterized by its high tetrahydrocannabinol (THC) content and low cannabidiol (CBD) levels, providing potent analgesic and anti-emetic effects. While the strain is used clinically in several regions, it remains in preclinical development for specific indications according to some pipeline summaries.

Brand names: Alaska
Other names: Tikun Olam Alaskahigh-THC strain

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on Alaska.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alaska.

Explore the full profile